Here's Won't Touch Teva: Why I Pass on the Generic Giant
Teva Pharmaceuticals sits at a crossroads of debt, generics, and a shifting pricing landscape. Here's why I won't tou...
Explore US market cap tilt retirement funds to adjust exposure. The intro covers when tilting helps and how to implement a balanced approach.
28,282 articlesTeva Pharmaceuticals sits at a crossroads of debt, generics, and a shifting pricing landscape. Here's why I won't tou...
Markets watch the debt path as deficits and entitlement costs rise. A budget watchdog warns that the current calm cou...
A major security misconfiguration at Anthropic left internal assets, including notes on an unreleased model and CEO r...
A leading wealth manager launches a new regional bank holding with $4.5 million in seed capital. Explore what this me...
Through May 2026, CWB rose about 19% year-to-date, underscoring the appeal of convertible bonds as a middle ground be...
Variant has closed a $222 million fund to back early-stage startups at the intersection of AI, crypto, and autonomy. ...
As the EU eyes strict MiCA enforcement ahead of the July 1 deadline, Binance could face a forced halt of services for...
XRP teeters near the $1 mark as July approaches, with AI-driven forecasts highlighting downside targets if the crucia...
The U.S. copper market, a roughly $20 billion arena, is flashing a breakout signal as cash costs go negative and by-p...
As Bloom Energy charts a post-2026 path, investors wonder if hydrogen fuel cells can sustain durable growth. This art...
Founders Fund has fully exited ETHZilla, and Peter Thiel has followed with a complete stake unload, underscoring a br...
Two decades after a flopped acting debut, David Ellison’s Skydance is moving from indie financier to potential indust...